From: "Goswami, Neela (CDC/DDID/NCHHSTP/DTE)" <nef7@cdc.gov>
Date: Wednesday, December 22, 2021 at 2:19 PM
To: CDC DDID NCHHSTP DTE TB Nurse Consultants <DDIDNCHHSTPTBNurseConsultants@cdc.gov>, CDC DDID NCHHSTP DTE TB Project Directors <DDIDNCHHSTPTBProjectDirectors@cdc.gov>, CDC DDID NCHHSTP DTE TB Control Officers <TBControl@cdc.gov>, CDC DDID NCHHSTP DTE FSB Field Staff <DDIDNCHHSTPTBFSBFieldStaff@cdc.gov>
Cc: CDC DDID NCHHSTP DTE FSB HQ <DDIDNCHHSTPTBFSBHQ@cdc.gov>, CDC DDID NCHHSTP DTE Medical Consultants <DDIDNCHHSTPDTEMedicalConsultants@cdc.gov>, CDC DDID NCHHSTP DTE Senior Staff <DDIDNCHHSTPTBSeniorStaff@cdc.gov>, Donna Wegener <dhwegener@tbcontrollers.org>
Subject: UPDATE: Rifampin supply - action may be needed

Dear Colleagues,

We have been notified that FDA will be updating their drug shortages website to announce a temporary national shortage of rifampin at: https://www.accessdata.fda.gov/scripts/drugshortages/.

CDC’s DTBE manages a TB Emergency Drug Stockpile (TEDS) that includes rifampin as part of its inventory.

Rifampin is available as direct assistance [DA] at no cost to interested TB programs that are directly funded under Cooperative Agreements PS20-2001 and PS18-1801. DTBE will prioritize release of rifampin to programs with patients being treated for TB disease who are at risk of treatment interruption because of the shortage. Rifampin will be released in order of expiration date and availability.

<table>
<thead>
<tr>
<th>LOT NO.</th>
<th>DRUG</th>
<th>MOU</th>
<th>DESCRIPTION</th>
<th>EXPIRATION</th>
<th>REMAINING</th>
</tr>
</thead>
<tbody>
<tr>
<td>3185930</td>
<td>Rifampin</td>
<td>CAP</td>
<td>300mg, 60s</td>
<td>01/31/2022</td>
<td>107 bottles</td>
</tr>
<tr>
<td>3185931</td>
<td>Rifampin</td>
<td>CAP</td>
<td>300mg, 60s</td>
<td>01/31/2022</td>
<td>141 bottles</td>
</tr>
<tr>
<td>3185933</td>
<td>Rifampin</td>
<td>CAP</td>
<td>300mg, 60s</td>
<td>01/31/2022</td>
<td>2632 bottles</td>
</tr>
<tr>
<td>3187555</td>
<td>Rifampin</td>
<td>CAP</td>
<td>300mg, 60s</td>
<td>4/30/2022</td>
<td>3840 bottles</td>
</tr>
<tr>
<td>3187559</td>
<td>Rifampin</td>
<td>CAP</td>
<td>300mg, 60s</td>
<td>4/30/2022</td>
<td>6246 bottles</td>
</tr>
<tr>
<td>3187560</td>
<td>Rifampin</td>
<td>CAP</td>
<td>300mg, 60s</td>
<td>4/30/2022</td>
<td>2316 bottles</td>
</tr>
</tbody>
</table>

To request medication, please email the following information to DTBE project officers Tracina Cropper (tcc3@cdc.gov) and Bruce Bradley (aei0@cdc.gov), and include your DTBE project officer on the cc line:

1. Justification providing assurance that drugs will be used in treating TB patients and that your jurisdiction has sufficient patient volume for the drugs to be used by their expiration date.

***Rifampin expiring 1/31/2022 will be prioritized for overnight shipping.***
2. Information to ensure secure receipt and storage of TB drugs - Point of contact information (Name, Telephone number, Email) and Shipping address.

3. Quantity requested – request amounts in unit of issue stated above (i.e., bottles)

Additionally, within a week of your email request to project officers, a direct assistance (DA) request should be submitted as an amendment in GrantSolutions by attaching the request letter to the amendment. DA request letters should be addressed to the *Grants Management Specialist in the Office of Grants Services, and signed by both the PI/PD and business official*. DA requests should include all information listed above. In addition, DA requests should include number of TB cases and completion of Treatment [COT] percentage as reported through the National TB Surveillance System.

**Our goal is to ensure patients with TB disease do not have treatment interrupted.**

Please contact your DTBE Project Officer or Tracina Cropper (tcc3@cdc.gov) if you have questions. Please continue to report problems obtaining TB drugs or diagnostics to NTCA using the standardized form at [http://www.tbcontrollers.org/](http://www.tbcontrollers.org/)

----------------------------

Neela D. Goswami, MD, MPH  
Acting Field Services Branch Chief  
Division of TB Elimination, NCHHSTP  
Centers for Disease Control and Prevention